Baroda BNP Paribas Health and Wellness Fund
The scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns.
Growthvine rating: 1/5 — ranked #86 of 87 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹9.93 (as of 2026-10-23) |
|---|
| AUM | ₹487 Cr |
|---|
| Expense ratio | 2.09% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Ankeet Pandya |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 1 year |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −11.93% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 77.3% of NIFTY Pharma's upside and 124.7% of its downside.
Market cap allocation
| Large cap | 32.1% |
|---|
| Mid cap | 46.5% |
|---|
| Small cap | 21.5% |
|---|
Concentration
| Top 5 holdings | 36.5% |
|---|
| Top 10 holdings | 58.4% |
|---|
| Total holdings | 33 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 8.6%
- Torrent Pharmaceuticals Ltd. — 7.9%
- Divis Laboratories Ltd. — 7.8%
- Ipca Laboratories Ltd. — 6.1%
- Laurus Labs Limited — 6.1%
- Lupin Ltd — 5.8%
- Apollo Hospitals Enterprises Ltd. — 5.3%
- Fortis Healthcare Ltd — 4.0%
- Dr. Lal Pathlabs Limited — 3.5%
- Mankind Pharma Limited — 3.3%
Top sectors
- Pharma & Biotech — 73.7%
- Healthcare — 19.8%
- Cash — 2.9%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 5.0% | Q1 (Top) | #15 of 76 |